Response to interferon beta-1a treatment in African American multiple sclerosis patients

Archives of Neurology

Volumn 62, Issue 11, 2005, Pages 1681-1683

  Cree, Bruce A C ^a   Al Sabbagh, Ahmad ^b   Bennett, Randy ^b   Goodin, Douglas ^a  

^a UCSF Multiple Sclerosis Center   (United States)

^b EMD SERONO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; STATISTICAL ANALYSIS;

ADJUVANTS, IMMUNOLOGIC; AFRICAN AMERICANS; AGE OF ONSET; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIALS; STATISTICS, NONPARAMETRIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 27744582897     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.62.11.1681     Document Type: Article

References (3)

1. Cree B, Khan O, Boudrette D, et al. Comparison of the clinical characteristics of African American and Caucasian American patients with multiple sclerosis. Neurology. 2004;63:2039-2045.
2. Panitch H, Goodin DS, Francis G, et al; EVIDENCE (EVidence of Interferon Doseresponse: European North American Comparative Efficacy) Study Group; University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon β-1a treatment regimens in MS: the EVIDENCE trial. Neurology. 2002;59:1496-1506.
3. Muir AJ, Bornstein JD, Killenberg PG; Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350:2265-2271.